Switch theme
Sign up to access all valuation multiples
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. Its sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
1978
9.9K+
LTM Revenue $3.2B
LTM EBITDA $932M
$23.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sartorius Stedim Biotech has a last 12-month revenue (LTM) of $3.2B and a last 12-month EBITDA of $932M.
In the most recent fiscal year, Sartorius Stedim Biotech achieved revenue of $3.1B and an EBITDA of $753M.
Sartorius Stedim Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sartorius Stedim Biotech valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.2B | XXX | $3.1B | XXX | XXX | XXX |
| Gross Profit | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| Gross Margin | 45% | XXX | 43% | XXX | XXX | XXX |
| EBITDA | $932M | XXX | $753M | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 24% | XXX | XXX | XXX |
| EBIT | $647M | XXX | $444M | XXX | XXX | XXX |
| EBIT Margin | 20% | XXX | 14% | XXX | XXX | XXX |
| Net Profit | $288M | XXX | $197M | XXX | XXX | XXX |
| Net Margin | 9% | XXX | 6% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $2.3B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Sartorius Stedim Biotech's stock price is EUR 193 (or $217).
Sartorius Stedim Biotech has current market cap of EUR 18.8B (or $21.1B), and EV of EUR 21.0B (or $23.5B).
See Sartorius Stedim Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $23.5B | $21.1B | XXX | XXX | XXX | XXX | $4.35 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Sartorius Stedim Biotech has market cap of $21.1B and EV of $23.5B.
Sartorius Stedim Biotech's trades at 7.5x EV/Revenue multiple, and 31.3x EV/EBITDA.
Equity research analysts estimate Sartorius Stedim Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sartorius Stedim Biotech has a P/E ratio of 73.2x.
See valuation multiples for Sartorius Stedim Biotech and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $21.1B | XXX | $21.1B | XXX | XXX | XXX |
| EV (current) | $23.5B | XXX | $23.5B | XXX | XXX | XXX |
| EV/Revenue | 7.3x | XXX | 7.5x | XXX | XXX | XXX |
| EV/EBITDA | 25.3x | XXX | 31.3x | XXX | XXX | XXX |
| EV/EBIT | 36.4x | XXX | 53.0x | XXX | XXX | XXX |
| EV/Gross Profit | 16.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 73.2x | XXX | 107.1x | XXX | XXX | XXX |
| EV/FCF | 56.5x | XXX | 44.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSartorius Stedim Biotech's last 12 month revenue growth is 9%
Sartorius Stedim Biotech's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Sartorius Stedim Biotech's rule of 40 is 37% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sartorius Stedim Biotech's rule of X is 53% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sartorius Stedim Biotech and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 24% | XXX | XXX | XXX |
| EBITDA Growth | 16% | XXX | 9% | XXX | XXX | XXX |
| Rule of 40 | 37% | XXX | 34% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 53% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 29% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sartorius Stedim Biotech acquired XXX companies to date.
Last acquisition by Sartorius Stedim Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Sartorius Stedim Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Sartorius Stedim Biotech founded? | Sartorius Stedim Biotech was founded in 1978. |
| Where is Sartorius Stedim Biotech headquartered? | Sartorius Stedim Biotech is headquartered in France. |
| How many employees does Sartorius Stedim Biotech have? | As of today, Sartorius Stedim Biotech has 9.9K+ employees. |
| Who is the CEO of Sartorius Stedim Biotech? | Sartorius Stedim Biotech's CEO is Dr. Rene Faber, PhD. |
| Is Sartorius Stedim Biotech publicy listed? | Yes, Sartorius Stedim Biotech is a public company listed on PAR. |
| What is the stock symbol of Sartorius Stedim Biotech? | Sartorius Stedim Biotech trades under DIM ticker. |
| When did Sartorius Stedim Biotech go public? | Sartorius Stedim Biotech went public in 1994. |
| Who are competitors of Sartorius Stedim Biotech? | Similar companies to Sartorius Stedim Biotech include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Sartorius Stedim Biotech? | Sartorius Stedim Biotech's current market cap is $21.1B |
| What is the current revenue of Sartorius Stedim Biotech? | Sartorius Stedim Biotech's last 12 months revenue is $3.2B. |
| What is the current revenue growth of Sartorius Stedim Biotech? | Sartorius Stedim Biotech revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Sartorius Stedim Biotech? | Current revenue multiple of Sartorius Stedim Biotech is 7.3x. |
| Is Sartorius Stedim Biotech profitable? | Yes, Sartorius Stedim Biotech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sartorius Stedim Biotech? | Sartorius Stedim Biotech's last 12 months EBITDA is $932M. |
| What is Sartorius Stedim Biotech's EBITDA margin? | Sartorius Stedim Biotech's last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of Sartorius Stedim Biotech? | Current EBITDA multiple of Sartorius Stedim Biotech is 25.3x. |
| What is the current FCF of Sartorius Stedim Biotech? | Sartorius Stedim Biotech's last 12 months FCF is $417M. |
| What is Sartorius Stedim Biotech's FCF margin? | Sartorius Stedim Biotech's last 12 months FCF margin is 13%. |
| What is the current EV/FCF multiple of Sartorius Stedim Biotech? | Current FCF multiple of Sartorius Stedim Biotech is 56.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
